In thyroid carcinoma, more general treatments are still useful, such as those acting on targets at the common beginning or end of the causal chain: BRAF and MAPK inhibitors for papillary carcinoma or PI3K inhibitors for follicular carcinomas [13]; and in other cancers, drugs acting on the early driving mutations [39]. This evidence concerns the gene BRAF and thyroid gland carcinoma.